LOGIN  |  REGISTER
Recursion
Amneal Pharmaceuticals

Molina Healthcare Announces Fourth Quarter and Year-End 2024 Earnings Release and Conference Call Dates

January 02, 2025 | Last Trade: US$332.38 3.12 -0.93

LONG BEACH, Calif. / Jan 02, 2025 / Business Wire / Molina Healthcare, Inc. (NYSE: MOH) today announced it will issue its earnings release for the fourth quarter and year ending December 31, 2024, after the market closes on Wednesday, February 5, 2025, and will host a conference call and webcast to discuss the earnings release on Thursday, February 6, 2025, at 8:00 a.m. Eastern Time. To access this interactive teleconference, dial (877) 883-0383 and enter the confirmation number, 6464707. A telephonic replay of the conference call will be available through Thursday, February 13, 2025, by dialing (877) 344-7529 and entering the confirmation number, 2353454.

A live broadcast of Molina Healthcare’s conference call will be available on the Company’s investor relations website, investors.molinahealthcare.com. A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast.

About Molina Healthcare

Molina Healthcare, Inc., a FORTUNE 500 company, provides managed healthcare services under the Medicaid and Medicare programs and through the state insurance marketplaces. For more information about Molina Healthcare, please visit molinahealthcare.com.

Assertio

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page